MDRNA, Inc. to Hold Second Quarter 2009 Results Conference Call on Thursday, July 30, 2009, at 8:30 a.m. Eastern Time

BOTHELL, WA--(Marketwire - July 23, 2009) -

MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a conference call with investors and security analysts on Thursday, July 30, 2009, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to provide a business update and discuss financial results for the 2nd quarter ended June 30, 2009. To participate in the live conference call, U.S. residents should dial 800-510-9836 and international callers should dial 617-614-3670. The participant passcode for the live conference call is 45176872. To access the 24-hour telephone replay, U.S. residents should dial 888-286-8010 and international callers should dial 617-801-6888. The participant passcode for the replay is 73400458.

Alternatively, to access the live audio webcast for this conference call via the Internet, please go to MDRNA’s website at http://www.mdrnainc.com approximately 15 minutes prior to the conference call in order to register and download any necessary software. A replay of the webcast will be available for 30 days following the event.

About MDRNA, Inc.

MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health by combining novel RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide superior therapeutic options. Our multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology and bioinformatics. We are applying this expertise to a single, integrated drug discovery platform that will be the engine for our clinical pipeline and a versatile platform for establishing broad therapeutic partnerships. We are also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that we expect to lead to safer and more effective RNAi-based therapeutics. By combining broad expertise in siRNA science with proven delivery platforms and a strong and growing IP position, MDRNA is well positioned as a leading RNAi therapeutics company and value-added collaborator for our research partners. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.